| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
The bioactive sphingolipid metabolite, sphingosine-1-phosphate (S1P), is known as regulator of many physiological and pathophysiological processes. We examined the effects of S1P on barrier functions using an in vitro blood-brain barrier (BBB) model. S1P decreased transendothelial electrical resistance (TEER) and increased the permeability of sodium fluorescein under normal culture condition. Next, we examined the role of S1P on BBB function under oxygen glucose deprivation (OGD)/ reoxygenation condition. OGD/reoxygenation induced the increment of S1P production in endothelial cells, pericytes and astrocytes. OGD/reoxygenation decreased the BBB barrier function. However, treatment of inhibitors of S1P synthesis enzyme or S1P transporter improved the BBB dysfunction induced by OGD/reoxygenation. Thus, inhibition of S1P signaling is considered to improve blood-brain barrier dysfunction induced by oxygen glucose deprivation.
|
